{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-153616","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2022-05-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.815873+00:00","generated_at":"2026-06-25T10:00:50.314924+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AVROBIO reports preclinical Pompe gene therapy data; >99% glycogen reduction in heart; trial start 2023","bullets":["Median GAA enzyme activity in bone marrow reached 300-534 nmol/h/mg (p<0.005) vs 4-6 in normal mice eight months post-infusion.",">99% glycogen reduction in heart with reversal of cardiac hypertrophy; >97% reduction in diaphragm, >85% in quadriceps.",">95% glycogen reduction in brain and >99% in spinal cord; improved locomotor function and blood-brain barrier crossing.","Stable engraftment at eight months with median vector copy numbers 1.9-3.6 per diploid genome; no clonal dominance observed.","AVROBIO plans to engage regulators in 2022 and initiate a clinical trial for AVR-RD-03 in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-153616","json":"https://secwatch.observer/filing/0001193125-22-153616.json","markdown":"https://secwatch.observer/filing/0001193125-22-153616.md","text":"https://secwatch.observer/filing/0001193125-22-153616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312522153616/0001193125-22-153616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312522153616/d322523d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T10:00:50.314924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}